Aktuelle Kongressbeiträge

Die folgenden ausgewählten Kongressbeiträge geben Ihnen einen Einblick in unsere Forschungsbereiche:

Ausgewählte Kongressbeiträge seit 2014

ISPOR 2018 in Barcelona

APPROPRIATE COMPARATOR IN GERMAN AMNOG BENEFIT ASSESSMENTS IN MELANOMA – A DYNAMIC SITUATION

DIVERSITY IN SAFETY DATA ANALYSIS IN GERMAN AMNOG BENEFIT ASSESSMENTS FOR MULTIPLE MYELOMA

FEASIBILITY OF EVALUATING THE BURDEN OF β-THALASSEMIA WITH GERMAN CLAIMS DATA

IMPLICATIONS OF THE FAST EVOLVING THERAPEUTIC LANDSCAPE ON APPROPRIATE COMPARATORS IN ONCOLOGICAL AMNOG BENEFIT ASSESSMENTS

LANDSCAPE ASSESSMENT OF PROSPECTIVE REAL-WORLD EVIDENCE STUDIES IN EUROPE

THE BURDEN OF HYPERKALEMIA IN GERMANY – A CLAIMS DATABASE ANALYSIS

 

ISPOR 2017 in Glasgow

AMNOG DOSSIERS AS A CHALLENGE FOR PHARMACEUTICAL COMPANIES

APPLICATION OF BALANCING TECHNIQUES IN STUDIES UTILIZING GERMAN ADMINISTRATIVE HEALTHCARE DATA

APPLICATION OF MIXED-METHOD STUDY DESIGNS IN HEALTH-ECONOMIC-RELATED STUDIES

APPLICATION STUDY OF THE EQ-5D-5L IN ONCOLOGY

CLINICAL COMPARISON OF FIRST-LINE PLATIN CHEMOTHERAPY

COST AND OPERATIONAL EFFICIENCY COMPARISON OF AN INTEGRATED VS. A MULTI-STEP SYSTEM

GERMAN AMNOG BENEFIT ASSESSMENT

NON-QUANTIFIABLE BENEFIT WITHIN THE GERMAN AMNOG SYSTEM

OVERCOMING THE LIMITATIONS OF CLAIMS DATA

RELEVANCE OF REAL-WORLD DATA IN GERMAN AMNOG SUBMISSIONS IN ONCOLOGY

SURVIVAL DIFFERENCES IN HEART FAILURE PATIENTS

THE IMPACT OF PATIENT PREFERENCE STUDIES IN THE GERMAN HEALTHCARE SYSTEM

TRANSITION FROM ORPHAN DRUG TO FULL ASSESSMENT IN THE GERMAN AMNOG SYSTEM

UTILIZATION AND EVALUATION OF DELPHI PANELS IN GERMAN AMNOG ASSESSMENTS

 

ISPOR 2016 in Wien

Are Criteria Commonly Used in the Benefit Assessment of Drugs Also Applicable to Medical Devices? A Systematic Literature Review

Patient Individual Therapy as Appropriate Comparator in AMNOG-Dossiers in the Field of Oncology: Status Quo and Strategic Implications for Pharmaceutical Companies

IMPACT OF TRIAL DESIGN ON PRICE DISCOUNTS AFTER EARLY BENEFIT ASSESSMENT (AMNOG) IN GERMANY

THE VALUE OF PATIENT REPORTED OUTCOMES IN GERMAN AMNOG DOSSIERS

 

ISPOR 2015 in Mailand

Real World Evidence (RWE) In Oncology – Status Quo In Germany

The Use of Real-World Evidence (RWE) to Support Market Access of Medical Devices: Implications for the German Setting

Prevalence and Incidence Estimations in German AMNOG Applications: The Role of Real-world Evidence (RWE)

Incidence and Prevalence Estimations Based on Claims Data – New Methodological Considerations

 

ISPOR 2015 in Philadelphia

Use of Real-world Evidence in German AMNOG Applications

 

ISPOR 2014 in Amsterdam

AMNOG Benefit Assessment for Oncologic and Orphan Drugs in Germany: Implications for Price Discounts

Burden of Disease Caused by Influenza in Germany: A Retrospective Claims Database Analysis

AMNOG Benefit Assessment for Oncologic and Orphan Drugs in Germany: Implications for Price Discounts

Burden of Disease Caused by Influenza in Germany: A Retrospective Claims Database Analysis